By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?term=Emergent+Biosolutions&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=c&recrs=k&age_v=&gndr=&type=&rslt=
COVID-19 Information

Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19 - 

  • BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for COVID-19 in severe hospitalized and high-risk patients
  • NIAID to include COVID-HIG product candidate in one of its clinical studies for assessment of treatments for COVID-19 upon availability of clinical material
  • Emergent will seek a path forward with the FDA for the development of COVID-HIG and possible use under Emergency Use Authorization (EUA)

 

 

Stage
Pre-clinical
Company Type
Late Onset Intervention